Global Targeted Radiopharmaceuticals Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Targeted Radiopharmaceuticals market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Targeted radiopharmaceuticals are a type of medicinal product that combines a biologically active molecule (known as a ligand or targeting agent) with a radioactive isotope (radionuclide). These radiopharmaceuticals are designed to deliver radiation specifically to certain cells, tissues, or organs in the body, with the goal of achieving precise and localized treatment or imaging.
The concept of targeted radiopharmaceuticals is based on the idea of using the biological specificity of the ligand to selectively bind to receptors or antigens present on the target cells. Once the ligand has bound to its target, the radioactive component emits radiation that can be used for therapeutic purposes or imaging.There are two main categories of targeted radiopharmaceuticals: targeted therapeutic radiopharmaceuticals and targeted diagnostic radiopharmaceuticals.
Targeted radiopharmaceuticals offer several advantages over traditional treatments or imaging agents, including increased specificity, reduced damage to healthy tissues, and the potential for personalized medicine approaches based on the patient"s specific disease characteristics. However, the development and use of targeted radiopharmaceuticals require careful consideration of the ligand"s biological properties, radionuclide characteristics, and safety profiles to ensure effective and safe medical applications.
The radiopharmaceuticals market had been experiencing steady growth and significant interest due to the increasing use of nuclear medicine procedures for diagnostic and therapeutic purposes. Radiopharmaceuticals are essential tools in nuclear medicine, and they play a crucial role in diagnosing various diseases, such as cancer, cardiovascular conditions, and neurological disorders.
The radiopharmaceuticals market had been growing steadily over the years. Factors contributing to this growth include advancements in radiopharmaceutical development, rising prevalence of cancer and cardiovascular diseases, and an aging population that drives the demand for diagnostic procedures.
This report is a detailed and comprehensive analysis for global Targeted Radiopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted Radiopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Targeted Radiopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Targeted Radiopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Targeted Radiopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Targeted Radiopharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Targeted Radiopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Bayer, Lantheus, Institute for Radioelements (IRE), Radiomedix, Curium Pharma, Clarity Pharmaceuticals, ROTOP, Ratio Therapeutics, Fusion Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Targeted Radiopharmaceuticals market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Targeted Therapeutic Radiopharmaceuticals
Targeted Diagnostic Radiopharmaceuticals
Market segment by Application
Targeted Therapy
Targeted Diagnosis
Major players covered
Novartis
Bayer
Lantheus
Institute for Radioelements (IRE)
Radiomedix
Curium Pharma
Clarity Pharmaceuticals
ROTOP
Ratio Therapeutics
Fusion Pharmaceuticals
Perspective Therapeutics
RayzeBio
Alpha-9 Theranostics
Radiopharm Theranostics
Telix Pharmaceuticals
Ariceum Therapeutics
Aktis Oncology
Navidea Biopharmaceuticals
Nucleus RadioPharma
SmartNuclide Biopharma
TetraKit Technologies
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Targeted Radiopharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Targeted Radiopharmaceuticals, with price, sales quantity, revenue, and global market share of Targeted Radiopharmaceuticals from 2020 to 2025.
Chapter 3, the Targeted Radiopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Targeted Radiopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Targeted Radiopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Targeted Radiopharmaceuticals.
Chapter 14 and 15, to describe Targeted Radiopharmaceuticals sales channel, distributors, customers, research findings and conclusion.
Targeted radiopharmaceuticals are a type of medicinal product that combines a biologically active molecule (known as a ligand or targeting agent) with a radioactive isotope (radionuclide). These radiopharmaceuticals are designed to deliver radiation specifically to certain cells, tissues, or organs in the body, with the goal of achieving precise and localized treatment or imaging.
The concept of targeted radiopharmaceuticals is based on the idea of using the biological specificity of the ligand to selectively bind to receptors or antigens present on the target cells. Once the ligand has bound to its target, the radioactive component emits radiation that can be used for therapeutic purposes or imaging.There are two main categories of targeted radiopharmaceuticals: targeted therapeutic radiopharmaceuticals and targeted diagnostic radiopharmaceuticals.
Targeted radiopharmaceuticals offer several advantages over traditional treatments or imaging agents, including increased specificity, reduced damage to healthy tissues, and the potential for personalized medicine approaches based on the patient"s specific disease characteristics. However, the development and use of targeted radiopharmaceuticals require careful consideration of the ligand"s biological properties, radionuclide characteristics, and safety profiles to ensure effective and safe medical applications.
The radiopharmaceuticals market had been experiencing steady growth and significant interest due to the increasing use of nuclear medicine procedures for diagnostic and therapeutic purposes. Radiopharmaceuticals are essential tools in nuclear medicine, and they play a crucial role in diagnosing various diseases, such as cancer, cardiovascular conditions, and neurological disorders.
The radiopharmaceuticals market had been growing steadily over the years. Factors contributing to this growth include advancements in radiopharmaceutical development, rising prevalence of cancer and cardiovascular diseases, and an aging population that drives the demand for diagnostic procedures.
This report is a detailed and comprehensive analysis for global Targeted Radiopharmaceuticals market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Targeted Radiopharmaceuticals market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Targeted Radiopharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Targeted Radiopharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Targeted Radiopharmaceuticals market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Targeted Radiopharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Targeted Radiopharmaceuticals market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Bayer, Lantheus, Institute for Radioelements (IRE), Radiomedix, Curium Pharma, Clarity Pharmaceuticals, ROTOP, Ratio Therapeutics, Fusion Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Targeted Radiopharmaceuticals market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Targeted Therapeutic Radiopharmaceuticals
Targeted Diagnostic Radiopharmaceuticals
Market segment by Application
Targeted Therapy
Targeted Diagnosis
Major players covered
Novartis
Bayer
Lantheus
Institute for Radioelements (IRE)
Radiomedix
Curium Pharma
Clarity Pharmaceuticals
ROTOP
Ratio Therapeutics
Fusion Pharmaceuticals
Perspective Therapeutics
RayzeBio
Alpha-9 Theranostics
Radiopharm Theranostics
Telix Pharmaceuticals
Ariceum Therapeutics
Aktis Oncology
Navidea Biopharmaceuticals
Nucleus RadioPharma
SmartNuclide Biopharma
TetraKit Technologies
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Targeted Radiopharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Targeted Radiopharmaceuticals, with price, sales quantity, revenue, and global market share of Targeted Radiopharmaceuticals from 2020 to 2025.
Chapter 3, the Targeted Radiopharmaceuticals competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Targeted Radiopharmaceuticals breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Targeted Radiopharmaceuticals market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Targeted Radiopharmaceuticals.
Chapter 14 and 15, to describe Targeted Radiopharmaceuticals sales channel, distributors, customers, research findings and conclusion.
Table of Contents
146 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Targeted Radiopharmaceuticals by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
